Chapter 16: HPV vaccines in immunocompromised women and men

Joel M. Palefsky, Maura L. Gillison, Howard D. Strickler

Research output: Contribution to journalArticlepeer-review

91 Scopus citations


HIV-positive as well as other immunocompromised women and men have increased risk of human papillomavirus (HPV)-associated anogenital and oral cancers. The effectiveness of a HPV vaccine to reduce the incidence of these tumors in immunocompromised individuals may depend on several factors, including the effects of immunocompromise on the response to vaccination, the extent of prior infection with the HPV types included in the vaccine, whether immunocompromised women and men have tumors that contain types of HPV not in the vaccines more often than the general population, and whether or not immunization occurs before immunocompromise is severe. Clinical studies are needed to determine HPV vaccine safety and effectiveness in different populations of immunocompromised women and men.

Original languageEnglish (US)
Pages (from-to)S140-S146
Issue numberSUPPL. 3
StatePublished - Aug 21 2006


  • HIV
  • HPV
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Chapter 16: HPV vaccines in immunocompromised women and men'. Together they form a unique fingerprint.

Cite this